| 1 |
33228395 | Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis. | 2021 Mar 2 |
3 |
| 2 |
33781947 | Pathophysiology and inhibition of cholesteryl ester transfer protein for prevention of cardiovascular diseases: An update. | 2021 Jul |
1 |
| 3 |
34101144 | Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects. | 2021 Jul |
4 |
| 4 |
34375108 | Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties. | 2021 Sep 23 |
3 |
| 5 |
34498872 | Toward a Best-in-Class Inhibitor of Cholesteryl Ester Transfer Protein (CETP). | 2021 Sep 23 |
1 |
| 6 |
34849601 | CETP-inhibitors: from HDL-C to LDL-C lowering agents? | 2021 Nov 26 |
2 |
| 7 |
33263263 | Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial. | 2020 Dec 15 |
2 |
| 8 |
30420679 | Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile. | 2019 Mar |
2 |
| 9 |
30567880 | Characterization of Anacetrapib Distribution into the Lipid Droplet of Adipose Tissue in Mice and Human Cultured Adipocytes. | 2019 Mar |
2 |
| 10 |
31331193 | Impact of ADCY9 Genotype on Response to Anacetrapib. | 2019 Jul 23 |
1 |
| 11 |
31832204 | Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case. | 2019 Dec |
4 |
| 12 |
28777919 | Binding profiles of cholesterol ester transfer protein with current inhibitors: a look at mechanism and drawback. | 2018 Aug |
2 |
| 13 |
28884824 | Pharmacokinetics and Pharmacodynamics of Anacetrapib Following Single Doses in Healthy, Young Japanese and White Male Subjects. | 2018 Feb |
2 |
| 14 |
29018035 | Trials and Tribulations of CETP Inhibitors. | 2018 Jan 5 |
2 |
| 15 |
29174438 | Mendelian randomization analysis of cholesteryl ester transfer protein and subclinical atherosclerosis: A population-based study. | 2018 Jan - Feb |
1 |
| 16 |
29498299 | Cardiovascular outcomes trial with anacetrapib in subjects with high cardiovascular risk - are major benefits REVEALed? | 2018 Apr |
1 |
| 17 |
29609759 | Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk. | 2018 May |
2 |
| 18 |
29630000 | What have we learnt from the clinical outcomes trials with the cetrapibs? | 2018 Aug |
1 |
| 19 |
30029099 | Plasma high density lipoproteins: Therapeutic targeting and links to atherogenic inflammation. | 2018 Sep |
1 |
| 20 |
30029292 | Pharmacokinetics and Pharmacodynamics of Anacetrapib in Black and White Healthy Subjects. | 2018 Dec |
1 |
| 21 |
30278356 | CETP inhibition, statins and diabetes. | 2018 Nov |
2 |
| 22 |
30347344 | Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists. | 2018 Nov |
1 |
| 23 |
28314859 | Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and E. | 2017 Jun |
3 |
| 24 |
28380664 | Chronic Administration of Anacetrapib Is Associated With Accumulation in Adipose and Slow Elimination. | 2017 Nov |
2 |
| 25 |
28432183 | Anacetrapib-driven triglyceride lowering explained: the fortuitous role of CETP in the intravascular catabolism of triglyceride-rich lipoproteins. | 2017 Jun |
1 |
| 26 |
28478132 | Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia. | 2017 Jun |
1 |
| 27 |
28729361 | CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects. | 2017 Sep |
4 |
| 28 |
28847206 | Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. | 2017 Sep 28 |
2 |
| 29 |
28961179 | Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias? | 2017 Sep 29 |
1 |
| 30 |
29263647 | Anacetrapib as a potential cardioprotective strategy. | 2017 |
1 |
| 31 |
29276295 | Cholesterol Ester Transfer Protein Inhibitor Review. | 2017 Oct |
1 |
| 32 |
26642232 | Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors? | 2016 |
1 |
| 33 |
26712818 | Disposition into Adipose Tissue Determines Accumulation and Elimination Kinetics of the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Mice. | 2016 Mar |
3 |
| 34 |
26966279 | Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein. | 2016 May |
5 |
| 35 |
27131642 | Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia. | 2016 Jun |
1 |
| 36 |
27171534 | Cholesteryl ester transfer protein inhibitors: challenges and perspectives. | 2016 Aug |
1 |
| 37 |
27215419 | [Impact of lipid metabolism parameters on the development and progression of coronary artery disease : An update]. | 2016 Jun |
2 |
| 38 |
27900865 | [Treatment of dyslipidemia - is here still place for CETP-inhibitors?] | Fall 2016 |
1 |
| 39 |
25079474 | Looking into the crystal ball-upcoming drugs for dyslipidemia. | 2015 Jan |
1 |
| 40 |
25651523 | Assessment of the persistence of anacetrapib and evacetrapib concentrations using two pharmacokinetic modeling approaches. | 2015 Jul |
2 |
| 41 |
25670362 | Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. | 2015 Jan-Feb |
4 |
| 42 |
25670366 | Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin. | 2015 Jan-Feb |
2 |
| 43 |
25743173 | Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. | 2015 May 30 |
1 |
| 44 |
25961461 | Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. | 2015 Jun |
2 |
| 45 |
24188894 | Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. | 2014 Jan 1 |
4 |
| 46 |
24380613 | Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility. | 2014 Jul |
1 |
| 47 |
24422575 | Future of cholesteryl ester transfer protein inhibitors. | 2014 |
1 |
| 48 |
24615657 | Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers. | 2014 Jul |
2 |
| 49 |
24618931 | Anacetrapib: a potential new therapy for dyslipidemia. | 2014 Sep-Oct |
2 |
| 50 |
24737712 | Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study. | 2014 Nov |
5 |